Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, has announced its latest developments in the global market. The company, which operates in the United States, Canada, Israel, and internationally, specializes in the development, manufacturing, and marketing of prescription and over-the-counter pharmaceutical products. In addition to this, it also produces active pharmaceutical ingredients which are primarily used in its finished dosage form products. The range of products offered by Taro is broad, spanning several therapeutic categories, including anti-inflammatory, anti-cancer, antipyretic, cardiovascular, CNS, and gastrointestinal. They are available in a variety of forms, such as tablets, creams, injections, and topical solutions, among others. These products are distributed directly to wholesalers, retail drug store chains, hospitals, mass merchandisers, and other direct customers, including healthcare institutions and private pharmacies. Founded in 1950 and headquartered in Haifa, Israel, Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd. As one of the leading pharmaceutical companies in the market, Taro aims to continue developing innovative and effective products to serve the needs of its customers.
Taro Pharmaceutical Industries's ticker is TARO
The company's shares trade on the NYSE stock exchange
They are based in Hawthorne, New York
There are 1001-5000 employees working at Taro Pharmaceutical Industries
It is taro.com
Taro Pharmaceutical Industries is in the Healthcare sector
Taro Pharmaceutical Industries is in the Drug Manufacturers - Other industry
The following five companies are Taro Pharmaceutical Industries's industry peers: